澳大利亚的真实世界数据反映了直接作用抗病毒治疗丙型肝炎在 12 周时具有非常高的持续病毒学应答率，并表明即使在没有治疗结束应答的患者中也具有高度可实现性。

Real-world Australian data reflect very high sustained virologic response at 12 weeks with direct acting antiviral therapy for hepatitis C and suggests highly achievable even in those without an end-of-treatment response.

机构信息

Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia.

Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.

出版信息

Intern Med J. 2019 May;49(5):666-669. doi: 10.1111/imj.14279.

DOI:10.1111/imj.14279

PMID:31083802

Abstract

There are limited real-world data on the efficacy of direct acting antiviral (DAA) therapy for hepatitis C (HCV) in Australia. In this study, the efficacy of DAA therapy for HCV was compared between cirrhotic and non-cirrhotic cohorts. Patients without end-of-treatment response (EoTR) were observed to ascertain likelihood of achieving sustained virological response at 12 weeks post-treatment (SVR12). A total of 334 patients with HCV was included. Overall SVR12 was 96.7% with minimal differences in SVR12 between the cirrhosis and non-cirrhosis groups (95.7 and 97.3%). There were 20 patients (5.99%) that failed to achieve an EoTR of which 80.0% (n = 16) went on to achieve SVR12. These results suggest DAA therapy is effective with high rates of SVR12 even in patients that do not achieve an EoTR.

摘要

澳大利亚针对丙型肝炎（HCV）的直接作用抗病毒（DAA）疗法的真实世界数据有限。本研究比较了肝硬化和非肝硬化队列中 DAA 治疗 HCV 的疗效。观察未达到治疗结束时应答（EoTR）的患者，以确定治疗后 12 周（SVR12）时实现持续病毒学应答的可能性。共纳入 334 例 HCV 患者。总体 SVR12 为 96.7%，肝硬化和非肝硬化组之间 SVR12 差异极小（分别为 95.7%和 97.3%）。有 20 名患者（5.99%）未能达到 EoTR，其中 80.0%（n=16）实现了 SVR12。这些结果表明，即使在未达到 EoTR 的患者中，DAA 治疗也非常有效，SVR12 率很高。